Dimethyl fumarate (DMF) is an immunomodulatory treatment for multiple sclerosis (MS).
Despite its wide clinical use, the mechanisms underlying clinical response are not …

Objective Immunological studies have demonstrated a plethora of beneficial effects of
dimethyl fumarate (DMF) on various cell types. However, the cellular and molecular targets …

Treatment with dimethyl fumarate (DMF) leads to lymphopenia and infectious complications
in a subset of patients with multiple sclerosis (MS). Here, we aimed to reveal immune …

Background Dimethyl fumarate (DMF) is a common treatment for multiple sclerosis (MS), but
its mechanisms of action are not fully understood. Targeted proteomics offers insights into …

Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple
sclerosis (MS), but their value to predict response to treatment, and their association with …

Aim Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing‐remitting
multiple sclerosis (RRMS) patients since it has shown immunomodulatory and …

Background: The precise mechanism of action of dimethyl fumarate (DMF) treatment in MS
remains unknown. Objective: To identify the changes in the blood lymphocyte profile of MS …

Background: Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy
and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially …

Background Dimethyl fumarate (DMF) is a disease-modifying therapy for patients with
relapsing-remitting multiple sclerosis (RRMS). T cells are major contributors to the …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …